Dishman Carbogen Amcis Ltd.

₹172.4

3.3 (1.9%)

DCAL Share Price

Pharmaceuticals & Biotechnology

As on August 19, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,685 Cr

P/E Ratio834.46

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	181.31	Bearish
10-DMA	186.71	Bearish
20-DMA	186.5	Bearish
50-DMA	184.87	Bearish
100-DMA	181.04	Bearish
200-DMA	201.98	Bearish

Historical Performance

1 Year

-36%

3 Years

13.6%

5 Years

-8.4%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	27,115	26,158	24,129	21,407	19,120
Total Expenditure	22,718	23,519	20,807	18,150	16,378
Other Income	509	508	278	491	386
Operating Profit	4,906	3,147	3,600	3,748	3,128
Interest	1,595	1,200	857	568	476
Depreciation	2,937	3,109	2,807	3,076	3,079
Profit Before Tax	193	-1,223	-546	-42	-650
Consolidated Net Profit	32	-1,534	-298	180	-1,651
Adjusted EPS	---	-10	-2	1	-11

Compounded Sales Growth

10 Years:9.6

5 Years:5.8

3 Years:4.8

TTM:0.7

Compounded Profit Growth

10 Years:-54.2

5 Years:-54.1

3 Years:-29

TTM:-62.6

Stock Price CAGR

10 Years:N/A

5 Years:-1.1

3 Years:4.4

TTM:-36.6

Return on Equity

10 Years:N/A

5 Years:-10.5

3 Years:-1.9

last year:0.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	314	314	314	314	314
Total Reserves	58,002	55,961	57,783	55,176	56,675
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	22,300	13,884	18,314	16,655	13,667
Other Current Liabilities	9,932	6,395	8,416	7,024	5,587
Short Term Borrowings	6,553	16,202	6,808	4,926	5,425
Total Liabilities	99,863	95,706	94,395	86,342	83,559
Capital Work in Progress	2,517	5,008	9,963	7,548	4,246
Long Term Loans & Advances	1,905	1,928	2,172	2,108	4,115
Currents Investments	254	233	1,770	2,925	1,164
Short Term Loans and Advances	802	790	1,210	1,895	1,976
Total Current Assets	22,004	19,282	19,184	18,387	17,041
Total Assets	99,863	95,706	94,395	86,342	83,559
Adjusted Book Value	372	359	371	354	363

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 834.46, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of 3.9%, indicating poor shareholder returns.
The stock carries a high beta of 1.8, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹4906 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹27115 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 633940.1

No. of Shares: 3677 (Approx)

Performance:-36.6%

-366059.9

NIFTY Performance: -3.9%

1 day Top Gainers